Lipigon Pharmaceuticals Current Valuation vs. Shares Outstanding
| LPGO Stock | SEK 0.19 0.01 5.00% |
For Lipigon Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lipigon Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lipigon Pharmaceuticals AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lipigon Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lipigon Pharmaceuticals AB over time as well as its relative position and ranking within its peers.
Lipigon |
Lipigon Pharmaceuticals Shares Outstanding vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lipigon Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Lipigon Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Lipigon Pharmaceuticals AB is rated fourth overall in current valuation category among its peers. It also is rated fourth overall in shares outstanding category among its peers creating about 3.63 of Shares Outstanding per Current Valuation. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lipigon Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Lipigon Current Valuation vs. Competition
Lipigon Pharmaceuticals AB is rated fourth overall in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is now estimated at about 26.63 Billion. Lipigon Pharmaceuticals adds roughly 5.58 Million in current valuation claiming only tiny portion of stocks in Biotechnology industry.
Lipigon Shares Outstanding vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Lipigon Pharmaceuticals |
| = | 5.58 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Lipigon Pharmaceuticals |
| = | 20.24 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Lipigon Shares Outstanding Comparison
Lipigon Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.
Lipigon Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lipigon Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lipigon Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Lipigon Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Lipigon Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Lipigon Pharmaceuticals AB develops drugs for lipid related diseases in Sweden. Lipigon Pharmaceuticals AB was founded in 2010 and is based in Ume, Sweden. Lipigon Pharmaceuticals is traded on Stockholm Stock Exchange in Sweden.
Lipigon Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lipigon Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lipigon Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lipigon Pharmaceuticals' important profitability drivers and their relationship over time.
Use Lipigon Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipigon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipigon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Lipigon Pharmaceuticals Pair Trading
Lipigon Pharmaceuticals AB Pair Trading Analysis
The ability to find closely correlated positions to Lipigon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipigon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipigon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipigon Pharmaceuticals AB to buy it.
The correlation of Lipigon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipigon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipigon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipigon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lipigon Pharmaceuticals position
In addition to having Lipigon Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small & Mid Caps ETFs Thematic Idea Now
Small & Mid Caps ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small & Mid Caps ETFs theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small & Mid Caps ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Lipigon Stock Analysis
When running Lipigon Pharmaceuticals' price analysis, check to measure Lipigon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipigon Pharmaceuticals is operating at the current time. Most of Lipigon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lipigon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipigon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lipigon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.